ArticleVirchows Archiv : an international journal of pathology2025
A practical approach to better identify NTRK 1-3 fusion-positive mesenchymal neoplasms by pan-Trk immunohistochemistry.
Article in Virchows Archiv : an international journal of pathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Detection of NTRK gene fusions in sarcomas: a comparative study of Pan-TRK immunohistochemistry, FISH, and RNA-Based NGS.Pathologica · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pan-Trk immunohistochemistry has become an affordable screening tool for tumors harboring NTRK1 - 3-rearrangements. However, false positive staining has been addressed especially in tumors with mesenchymal origin. As a positive staining triggers reflex testing, a better understanding about pan-Trk immunohistochemistry in these tumors has become necessary. In this work, we extensively studied pan-Trk IHC in a large cohort of mesenchymal neoplasms using two antibody clones: EPR17341 (RTU Assay, Roche/Ventana) and A7H6R (Cell Signaling Technologies). Whole slide sections of 809 individual cases, including 35 subtypes of mesenchymal neoplasms, were analyzed by two different pan-Trk antibodies. Any positivity above background in > 1% of tumor cells was classified as positive. Positive stained cases were molecularly analyzed. The specificity of clone EPR17341 was 78% and showed 21.9% false positive staining (177/809). Forty-five percent (80/177) of the false positive stained cases harbored a non-NTRK-gene fusion. When comparing the two antibodies in mesenchymal neoplasms, clone A7H6R showed 80% less false positive stains compared to clone EPR17341. Additionally, three tumors harboring a NTRK1-fusion were newly identified (0.4%) and reclassified in our cohort. Our work showed a high false positive rate in mesenchymal neoplasms using clone EPR17341. Clone A7H6R demonstrated a higher specificity and therefore could be considered in clinical practice for screening mesenchymal tumors for NTRK1 - 3-rearrangements, eventually leading to less unnecessary reflex testing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.